July 13, 2026

Breast Cancer: Tailoring Radiotherapy Based on Nodal Response to Primary Chemotherapy

As reported in The Lancet Oncology by Mauritz et al, 10-year follow-up of a Dutch prospective registry study indicated that tailoring postoperative locoregional radiotherapy based on nodal response to...

The ASCO Post

July 13, 2026

Breast Cancer: Tailoring Radiotherapy Based on Nodal Response to Primary Chemotherapy

As reported in The Lancet Oncology by Mauritz et al, 10-year follow-up of a Dutch prospective registry study indicated that tailoring postoperative locoregional radiotherapy based on nodal response to...

The ASCO Post

July 08, 2026

Intraoperative Margin Assessment With Specimen PET/CT Imaging in Early Breast Cancer

In a European trial (BrIMA) reported in JAMA Surgery, Göker et al found that specimen PET/CT imaging was associated with improved detection of positive margins in surgery for early breast cancer.

The ASCO Post

July 08, 2026

No Survival Benefit From Chemoradiotherapy After D2 Gastrectomy in Gastric Cancer

In a phase III trial, the addition of radiotherapy to the SOX chemotherapy regimen did not improve survival in patients with T4 and/or node-positive gastric adenocarcinoma who underwent D2 gastrectomy...

The ASCO Post

June 22, 2026

ASE Details M-TEER Imaging Guidance

The guideline emphasizes standardized image orientation and heart team communication during mitral valve transcatheter edge-to-edge repair.

MDSpire News

June 18, 2026

FDA Warns of Ongoing Breast Biopsy Needle Shortage

The U.S. Food and Drug Administration (FDA) issued notice of supply chain interruptions for stereotactic breast biopsy needles due to recent supplier issues. The agency noted that the duration of the ...

The ASCO Post

June 10, 2026

Early Study Finds Intralesional PD-1 Blockade ‘Promising’ for Oral Cancer Prevention

Intralesional nivolumab reduced the size of precancerous lesions and preserved quality of life in patients with oral epithelial dysplasia, according to results from a first-in-human phase I dose-escal...

The ASCO Post

June 10, 2026

Early Study Finds Intralesional PD-1 Blockade ‘Promising’ for Oral Cancer Prevention

Intralesional nivolumab reduced the size of precancerous lesions and preserved quality of life in patients with oral epithelial dysplasia, according to results from a first-in-human phase I dose-escal...

The ASCO Post

June 03, 2026

Vaccine Plus Pembrolizumab Reduces Risk of Recurrence in High-Risk, Resected Melanoma

The combination of the individualized neoantigen therapy intismeran autogene and pembrolizumab led to an improvement in recurrence-free survival and distant metastasis–free survival rates compared wit...

The ASCO Post

June 03, 2026

Vaccine Plus Pembrolizumab Reduces Risk of Recurrence in High-Risk, Resected Melanoma

The combination of the individualized neoantigen therapy intismeran autogene and pembrolizumab led to an improvement in recurrence-free survival and distant metastasis–free survival rates compared wit...

The ASCO Post